GNI Group Ltd. provided an update on the subject enrollment in Phase III clinical trial in China of F351 (generic name: Hydronidone) for HBV-induced liver fibrosis conducted by one of main subsidiaries, Beijing Continent Pharmaceuticals Co. Ltd. As of May 19, 2023, Continent has completed the enrollments of 124 subjects, which is 50% of the target enrollment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,510 JPY | 0.00% | +2.62% | -11.31% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.31% | 795M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- 2160 Stock
- News GNI Group Ltd.
- Beijing Continent Achieves Mid-Point Subject Enrollment for F351 Phase III Clinical Trial in China